Hong Kong Insurance Stock News

Dividend proposal and earnings results set the tone for Xinyi Glass Xinyi Glass Holdings (SEHK:868) has drawn investor attention after reporting full year 2025 earnings, together with a proposed final cash dividend of HK$0.215 per share that will go to a shareholder vote in May. See our latest analysis for Xinyi Glass Holdings. The latest earnings release and dividend proposal have come alongside a strong run in the share price, with a 90 day share price return of 20.89% and year to date...

Akeso (SEHK:9926) is back in focus after presenting long term survival data for its bispecific antibody cadonilimab in advanced cervical cancer and announcing a new glioblastoma combo trial collaboration with INOVIO. See our latest analysis for Akeso. Akeso shares closed at HK$107.3 after a 5.2% 1 day share price return. While the 30 day share price return of 6.34% contrasts with a 13.75% decline over 90 days, the 47.19% 1 year total shareholder return and 173.03% 3 year total shareholder...

Earnings and dividend decisions put Hong Kong Exchanges and Clearing (SEHK:388) in focus Hong Kong Exchanges and Clearing (SEHK:388) is on investors’ radar after reporting full year 2025 results with revenue of HK$29,161 million and net income of HK$17,754 million, alongside a higher second interim dividend of HK$6.52 per share. See our latest analysis for Hong Kong Exchanges and Clearing. The latest earnings, higher second interim dividend and upcoming board refresh arrive as the shares...

Upcoming board meeting puts focus on results and dividend policy China Oilfield Services (SEHK:2883) has scheduled a board meeting on 24 March 2026 to approve its 2025 annual results and consider a final dividend, giving investors a clear date for key information on earnings and capital returns. See our latest analysis for China Oilfield Services. At a share price of HK$10.2, China Oilfield Services has seen momentum build recently, with a 30 day share price return of 13.97% and a 1 year...

Sales slump and land buys put China Overseas Land & Investment in focus China Overseas Land & Investment (SEHK:688) has come under closer investor scrutiny after reporting a 35.9% year-on-year drop in February 2026 contracted sales value and a 45% decline in sales area. Across January and February 2026, contracted sales value was RMB 22.942b, down 9% year-on-year. At the same time, the group purchased new land in Hong Kong and Baoding that could shape its future project pipeline. See our...

China Mengniu Dairy (SEHK:2319) is back in focus after the company flagged a 7% to 8% revenue decline and slightly lower margins for 2025, alongside plans for sizeable asset impairment provisions. See our latest analysis for China Mengniu Dairy. The revenue warning and impairment plans arrive after a mixed price pattern, with a 1 day share price return of 6.95% at HK$16.16, a 30 day share price return of 8.55%, and a 1 year total shareholder return of 11.88% that extends to 57.69% over five...

InnoCare Pharma (SEHK:9969) has drawn fresh attention after China’s drug regulator granted priority review to its next generation TRK inhibitor zurletrectinib for pediatric NTRK fusion solid tumors, alongside inclusion in the CDE’s SPARK Program. See our latest analysis for InnoCare Pharma. The priority review news comes after a mixed stretch for the shares. A 1-day share price return of 5.44% lifted the stock to HK$11.83, while the 30-day and 90-day share price returns of 7.87% and 17.10%...

CGN New Energy Holdings (SEHK:1811) has announced a leadership change, with long serving chairman and executive director Zhang Zhiwu stepping down due to job arrangements. Hu Guangyao will take over key board roles. See our latest analysis for CGN New Energy Holdings. The leadership reshuffle comes as CGN New Energy Holdings trades at HK$2.78, with recent momentum reflected in a 30 day share price return of 8.59% and a 1 year total shareholder return of 24.26%. This indicates improving...

Why Abbisko Cayman's Latest Earnings Matter for Investors Abbisko Cayman (SEHK:2256) is back in focus after releasing full year 2025 results, reporting sales of CNY612.12 million and net income of CNY55.25 million, alongside basic and diluted EPS of CNY0.09 from continuing operations. See our latest analysis for Abbisko Cayman. The earnings release appears to have shifted sentiment in the short term, with a 1 day share price return of 4.76% to HK$11.88. However, the 90 day share price return...

Why Black Sesame International Holding is back on investor radars Black Sesame International Holding (SEHK:2533) has drawn fresh attention after saying it expects more than 68% year on year revenue growth in 2025 from advanced driver assistance and robotics, while still forecasting a net loss. See our latest analysis for Black Sesame International Holding. The recent profit warning, paired with expectations for over 68% revenue growth and fresh capital from a HK$538 million share...

China Qinfa Group Limited announced in February 2026 that it expects to post a loss after tax of up to RMB 98,000,000 for 2025, compared with a profit of about RMB 556,370,000 in 2024. The guidance reveals that while discontinued operations are forecast to lose up to RMB 226,000,000, the Group’s continuing operations are still expected to generate up to RMB 128,000,000 in profit. We will now examine how this swing from profit to loss, driven largely by discontinued operations, shapes China...

Board meeting puts dividend and 2025 results in focus China Life Insurance (SEHK:2628) has set March 25, 2026 for a board meeting to approve its 2025 annual results and consider a final dividend, an event that may be important for shareholders tracking capital returns. This meeting will provide fresh information on the insurer’s financial performance, how management is thinking about capital allocation, and what that could mean for future cash returns through dividends. See our latest...

JNBY Design (SEHK:3306) is back in focus after reporting half year results to 31 December 2025, with higher sales and net income, as well as an interim dividend of HK$0.52 per share. See our latest analysis for JNBY Design. The latest half year results and higher interim dividend come as the share price trades at HK$21.18, with a 30 day share price return of 7.95% and a 1 year total shareholder return of 52%. This suggests momentum has been building over both shorter and longer periods. If...

CK Hutchison Holdings (SEHK:1) is back in focus after intensifying its legal fight with Panama over the seizure of two Panama Canal ports, pursuing about US$2b in damages through international arbitration. See our latest analysis for CK Hutchison Holdings. At a share price of HK$61.55, CK Hutchison has a 90 day share price return of 11.71% and a year to date share price return of 13.98%. Its 1 year total shareholder return of 30.45% and 3 year total shareholder return of 53.26% point to...

Why JD Logistics’ latest earnings matter for shareholders JD Logistics (SEHK:2618) released fourth quarter and full year 2025 results, giving investors fresh detail on revenue, profit, and how its expanding logistics footprint and on demand delivery integration are feeding into the business. See our latest analysis for JD Logistics. The latest earnings release appears to have shifted sentiment quickly, with a 1 day share price return of 22.98% and a 7 day share price return of 13.07%...

WEILONG Delicious Global Holdings (SEHK:9985) has called a board meeting for 26 March 2026 to approve its 2025 annual results and consider a potential dividend, putting earnings quality and shareholder returns in sharper focus for investors. See our latest analysis for WEILONG Delicious Global Holdings. At a share price of HK$11.45, WEILONG Delicious Global Holdings has seen a 1 day share price return of 3.62%, while its 30 day share price return of 8.03% contrasts with a 1 year total...

If you are wondering whether InSilico Medicine Cayman TopCo is attractively priced or starting to look stretched, you are in the right place for a clear valuation breakdown. The share price closed at HK$55.5, with a 7 day return of 10.4% decline, a 30 day return of 10.7% decline, and a year to date return of 47.7%, which may signal changing views on its potential and risk. Recent attention on InSilico Medicine Cayman TopCo has been shaped by company specific news in the pharmaceuticals and...

CSPC Pharmaceutical Group (SEHK:1093) just received U.S. FDA clearance to start clinical trials for SYH2059, an inhaled PDE4B inhibitor for pulmonary fibrosis, highlighting its respiratory pipeline on an international stage. See our latest analysis for CSPC Pharmaceutical Group. That FDA green light comes after a series of fresh trial approvals in China for hemophilia and asthma treatments. It also arrives as CSPC Pharmaceutical Group’s 90 day share price return of 25.10% and 1 year total...

Why Morgan Stanley Is Flagging China Tower Now Morgan Stanley’s latest Asia Pacific report singles out China Tower (SEHK:788) as a defensive Hong Kong stock, highlighting its high dividends and relatively low share price volatility during a period of geopolitical tension in the region. See our latest analysis for China Tower. At a last close of HK$11.06, China Tower’s recent share price return has been mixed, with a 1 day gain of 0.73% and a 30 day share price return of 1.94%, but a 90 day...

Mobvista (SEHK:1860) has drawn fresh attention after issuing 2025 earnings guidance that points to higher revenue and a sharp profit increase, largely tied to its Mintegral advertising platform and improved operating efficiency. See our latest analysis for Mobvista. The guidance has arrived at a time when Mobvista’s recent momentum has been mixed, with a 2.33% 1 day share price return and 6.89% 7 day share price return contrasting with weaker 90 day and year to date share price returns. At...

Why China Telecom’s GLOMO wins are back on investors’ radar Fresh recognition for China Telecom (SEHK:728) at the 2026 Mobile World Congress, including multiple Global Mobile Awards tied to satellite connectivity and digital education, has put the stock back in focus for many investors. See our latest analysis for China Telecom. The recent GLOMO awards arrive as China Telecom’s share price trades at HK$5.1, with short term share price returns in positive territory but a 90 day share price...

Phase 2 UBT251 data puts obesity pipeline in focus United Laboratories International Holdings (SEHK:3933) has drawn fresh attention after its subsidiary completed a Chinese phase 2 trial of UBT251, a GLP-1, GIP and glucagon triple agonist for overweight and obesity. See our latest analysis for United Laboratories International Holdings. The phase 2 obesity data lands at a time when the share price has a 1 month share price return of 11.39% and a year to date share price return of 12.53%,...

Why Pacific Basin Shipping’s Latest Earnings Matter for Investors Pacific Basin Shipping (SEHK:2343) has just reported its full year 2025 results, with sales of US$2,081.04 million and net income of US$58.17 million, alongside commentary on shareholder returns and capital allocation. The company also pointed to a 46% total shareholder return, a new US$250 million sustainability linked facility, and an ongoing share buyback. Together, these factors frame how management is currently thinking...

In February 2026, Earendil Labs announced a collaboration with WuXi XDC Cayman Inc., securing an exclusive global license to WuXi XDC’s proprietary WuXiTecan-2 payload-linker platform for multiple targets, alongside up to approximately US$885 million in potential upfront and milestone payments plus tiered royalties. The partnership combines Earendil’s AI-driven antibody discovery with WuXi XDC’s integrated bioconjugate CRDMO capabilities, positioning WuXi XDC as a key enabler in...